These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 30288408)

  • 1. Impact of the "Linked Evidence Approach" Method on Policies to Publicly Fund Diagnostic, Staging, and Screening Medical Tests.
    Merlin TL; Hiller JE; Ryan P
    MDM Policy Pract; 2016; 1(1):2381468316672465. PubMed ID: 30288408
    [No Abstract]   [Full Text] [Related]  

  • 2. Health technology assessment in Australia: a role for clinical registries?
    Scott AM
    Aust Health Rev; 2017 Mar; 41(1):19-25. PubMed ID: 27028134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The "linked evidence approach" to assess medical tests: a critical analysis.
    Merlin T; Lehman S; Hiller JE; Ryan P
    Int J Technol Assess Health Care; 2013 Jul; 29(3):343-50. PubMed ID: 23769128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence-based funding of new imaging applications and technologies by Medicare in Australia: How it happens and how it can be improved.
    Hill H; Mittal R; Merlin T
    J Med Imaging Radiat Oncol; 2022 Mar; 66(2):215-224. PubMed ID: 35243777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health Technology Assessment for Molecular Diagnostics: Practices, Challenges, and Recommendations from the Medical Devices and Diagnostics Special Interest Group.
    Garfield S; Polisena J; S Spinner D; Postulka A; Y Lu C; Tiwana SK; Faulkner E; Poulios N; Zah V; Longacre M
    Value Health; 2016; 19(5):577-87. PubMed ID: 27565275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of the 'linked evidence approach' to guide policy on the reimbursement of personalized medicines.
    Merlin T
    Per Med; 2014 Jun; 11(4):435-448. PubMed ID: 29783477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical effectiveness and cost-effectiveness of technologies used to visualise the seizure focus in people with refractory epilepsy being considered for surgery: a systematic review and decision-analytical model.
    Burch J; Hinde S; Palmer S; Beyer F; Minton J; Marson A; Wieshmann U; Woolacott N; Soares M
    Health Technol Assess; 2012; 16(34):1-157, iii-iv. PubMed ID: 22985954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nutrition and health technology assessment: when two worlds meet.
    Poley MJ
    Front Pharmacol; 2015; 6():232. PubMed ID: 26539116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A preliminary survey on the influence of rapid health technology assessments.
    Hailey D
    Int J Technol Assess Health Care; 2009 Jul; 25(3):415-8. PubMed ID: 19619362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Measurement Uncertainty in Health Technology Assessments (HTAs) of In Vitro Tests.
    Smith AF; Messenger M; Hall P; Hulme C
    Pharmacoeconomics; 2018 Jul; 36(7):823-835. PubMed ID: 29502176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Funding policies and postabortion long-acting reversible contraception: results from a cluster randomized trial.
    Rocca CH; Thompson KM; Goodman S; Westhoff CL; Harper CC
    Am J Obstet Gynecol; 2016 Jun; 214(6):716.e1-8. PubMed ID: 26692178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland.
    Schmitz S; McCullagh L; Adams R; Barry M; Walsh C
    Pharmacoeconomics; 2016 Sep; 34(9):925-37. PubMed ID: 27034245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries.
    Maynou L; Cairns J
    Health Policy; 2019 Feb; 123(2):130-139. PubMed ID: 30477736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decision making in surgical treatment of chronic low back pain: the performance of prognostic tests to select patients for lumbar spinal fusion.
    Willems P
    Acta Orthop Suppl; 2013 Feb; 84(349):1-35. PubMed ID: 23427903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.
    Siebert U; Rochau U; Claxton K
    Z Evid Fortbild Qual Gesundhwes; 2013; 107(9-10):575-84. PubMed ID: 24315327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transparency vs. closed-door policy: do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis.
    Fischer KE; Rogowski WH; Leidl R; Stollenwerk B
    Health Policy; 2013 Oct; 112(3):187-96. PubMed ID: 23664301
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.